Pathologists Vary in Suggested Therapy for Melanocytic Lesions

Share this content:
Pathologists Vary in Suggested Therapy for Melanocytic Lesions
Pathologists Vary in Suggested Therapy for Melanocytic Lesions

TUESDAY, Dec. 20, 2016 (HealthDay News) -- Pathologists have wide variability in treatment suggestions for melanocytic lesions, according to a study published in the January issue of the Journal of the American Academy of Dermatology.

Kachiu C. Lee, M.D., from Brown University in Providence, R.I., and colleagues conducted a survey to assess variability in 207 pathologists' treatment suggestions for melanocytic lesions in their reports.

The researchers found that 15 percent of pathologists reported never including suggestions and 7 percent reported always including suggestions. Improved care (79 percent), clarification (68 percent), and legal liability (39 percent) were cited as reasons for offering suggestions, while referring physician preference (48 percent), lack of clinical information (44 percent), and expertise (29 percent) were cited reasons for not offering suggestions. Offering suggestions were associated with training and caseload (P < 0.05). Suggestions were most consistent for mild/moderate dysplastic nevi and melanoma. For melanoma in situ, 9 percent of pathologists made treatment suggestions that undertreated legions and 15 percent made suggestions overtreating lesions, based on National Comprehensive Cancer Network (NCCN) guidelines. Seven percent of pathologists made treatment suggestions that undertreated lesions for invasive melanoma, based on NCCN guidelines.

"These findings may inform efforts to reduce treatment variability and optimize patterns of care delivery for patients," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

FDA Approves First Generic Under-the-Tongue Suboxone

FDA Approves First Generic Under-the-Tongue Suboxone

May only be prescribed by Drug Addiction Treatment Act-certified prescribers

Kellogg's Honey Smacks Cereal Recalled Due to Salmonella Risk

Kellogg's Honey Smacks Cereal Recalled Due to <i>Salmonella</i> ...

Twenty-four people have been hospitalized, but no deaths have been reported

Portable Music Player Use Linked to Hearing Loss in Children

Portable Music Player Use Linked to Hearing Loss ...

Increased odds of high-frequency hearing loss with portable music player use

is free, fast, and customized just for you!




Already a member?

Sign In Now »